Moderna and Merck presented Phase 3 data for intismeran, a customized personalized mRNA-based cancer vaccine, showing improved outcomes for melanoma patients and marking the first Phase 3 success for the program. Moderna CEO Stéphane Bancel said the companies plan to submit for FDA approval in 2027 and are preparing to test the platform across other cancers. The development caps a decade-long effort and follows years of vaccine experimentation setbacks across oncology, positioning personalized mRNA therapeutics as a more durable R&D bet for both companies. While longer-term follow-up and expansion cohorts will determine durability, today’s readout resets expectations for what personalized vaccine approaches can achieve within a defined regulatory path.